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Abstract
Background Hidradenitis suppurativa (HS) is a chronic skin disease characterized by inﬂammatory lesions that ﬂare
unpredictably. The impact of weekly adalimumab (ADAew) on HS ﬂare is not well-characterized.
Objective To evaluate the impact of disease ﬂare on health-related quality of life (HRQOL) in moderate-to-severe HS
patients and to determine the effect of ADAew on disease ﬂare using integrated data from two phase 3 trials over
36 weeks.
Methods In period A (12 weeks), Dermatology Life Quality Index (DLQI) score change from baseline was compared in
patients who ﬂared and those who did not, regardless of treatment. The proportion of patients experiencing ﬂare, dura-
tion of ﬂare and time to ﬂare was evaluated for ADAew vs. placebo (PBO). In period B (24 weeks), proportion of patients
experiencing ﬂare who received continuous ADAew treatment through 36 weeks was assessed.
Results HRQOL was markedly improved among those who did not experience ﬂare. In period A, the proportion of
patients who experienced ﬂare was signiﬁcantly lower with ADAew vs. PBO (12.3% vs. 35.3%, P < 0.001). ADAew
patients also had longer time to ﬁrst ﬂare (101 days vs. 57 days; P < 0.001) and shorter ﬂare duration (18.9 days vs.
32.0 days, respectively; P = 0.001) vs. PBO. Through 36 weeks of treatment, 20.2% of ADAew patients ﬂared, and for
those who achieved at least a partial clinical response to ADAew at 12 weeks, only 5.7% ﬂared.
Conclusions Flare reduction is an important measure in HS that correlates with clinically meaningful improvement in
HRQOL. ADAew reduces HS ﬂare through 12 and subsequent 36 weeks of treatment.
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Introduction
Hidradenitis suppurativa (HS) is a chronic, painful and debilitat-
ing skin disease of the hair follicle. It usually begins in young
adulthood and is characterized by recurrent inflammatory
abscesses and nodules in inverse body areas.1–3 Prevalence esti-
mates of HS vary between 0.1% in the United States and 1–2% in
European countries, depending on how and where data are col-
lected.1–3 While the exact underlying cause remains unknown,
HS does have a genetic link in approximately one-third
of patients4 and is strongly correlated with smoking and high
body mass index.5–7
The clinical course of HS is highly variable6,8,9 with skin
lesions flaring throughout the natural course of the disease.10
The timing and magnitude of disease flares in HS cannot be
accurately predicted, though premenstrual flare is commonly
reported.6 Many patients with HS also experience prodromal
symptoms, such as fatigue, malaise, headache, nausea, skin ery-
thema, paresthesia and itching prior to HS flare.11
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Flare has been recognized as an important outcome by HS
patients as well as clinicians even though its effect on quality of
life unknown. In a rigorous international Delphi exercise to
define the key outcomes for clinical trials in HS, experts and
patients from 19 countries across four continents reached con-
sensus regarding inclusion of flare frequency and duration in the
core domain set.12 As treatment for HS depends on clinical stag-
ing as well as frequency and duration of flares, HS clinical trials
should evaluate a medication’s effect on flares in addition to
clinical response to demonstrate efficacy.10,12
Adalimumab (ADA), a monoclonal antibody targeting
tumour necrosis factor-alpha, is approved for the treatment of
HS. However, the effect of ADA on HS flares has not been stud-
ied. By integrating data from the two phase 3 studies of ADA in
HS (PIONEER I and II), we first evaluated the impact of HS dis-
ease flare on patients’ health-related quality of life (HRQOL) to
demonstrate the clinical importance of flare. We then assessed
the proportion of patients experiencing flare, time to flare and
duration of flare in those treated with weekly ADA (ADAew) or
placebo (PBO) over 12 weeks. To understand the longer-term
impact of ADA on flare, we evaluated the flare incidence over
the entire 36-week period in patients receiving continuous
ADAew.
Materials and methods
Patients
Eligible patients were men and non-pregnant women aged
18 years or older with a diagnosis of HS ≥ 1 year prior to base-
line who had stable disease for at least 2 months before screen-
ing. Patients had lesions in ≥ 2 distinct body areas (Hurley Stage
II or III in at least one area), total abscess and inflammatory
nodule (AN) count ≥ 3 at baseline, and an inadequate response
to a ≥ 3-month trial of oral antibiotics to treat HS.
Patients were excluded if they received prior treatment with
ADA or another anti-tumour necrosis factor therapy, had a
draining fistula count > 20 at baseline or had received oral
antibiotics for HS ≤ 28 days before baseline (PIONEER I only)
or analgesics for HS-related pain or prescription topical treat-
ment for HS ≤ 14 days prior to baseline.13
Study design and treatment
This analysis integrated data from two phase 3 studies (PIO-
NEER I [NCT01468207] and II [NCT01468233])13 and the ini-
tial portion of the open-label extension (OLE) (NCT01635764)
that paralleled the 36 weeks of the controlled portion of the
PIONEER trials for patients who escaped early.14 The PIONEER
I and II trials had similar study designs (Fig. 1), with each hav-
ing two double-blind periods (a 12-week period A and 24-week
period B). During period A, patients were randomized 1:1 to
receive ADA 160 mg at week 0, 80 mg at week 2, and 40 mg
every week or matching PBO starting at week 4. In period B,
patients taking ADA from period A were re-randomized to
receive ADAew, ADA every other week (ADAeow), or PBO,
while PBO patients from period A were switched to ADAew
(PIONEER I) or continued with PBO (PIONEER II) from weeks
12 to 36. The primary endpoint at week 12 was HS clinical
response (HiSCR), a validated assessment of HS treatment effi-
cacy.15,16 HiSCR is defined as a ≥ 50% improvement in total AN
count, with no increase in abscess and no increase in draining
fistula counts relative to baseline. While all patients were eligible
to enter the OLE after completing period B, patients were res-
cued into the OLE during period B if they lost response or expe-
rienced a worsening or absence of improvement (see Fig. 1 for
definitions).
Assessments
Flare assessment HS disease flare was defined a priori as a
≥ 25% increase in the total AN count with a minimum increase
of 2 AN relative to baseline. This measure was developed with
the intent to approximate flare as closely as possible to the real-
world clinical presentation, as there is no currently available
objective and measurable definition for flare in HS.
To understand the impact of flare on patients’ HRQOL,
change in Dermatology Life Quality Index (DLQI) score from
baseline was evaluated in those who experienced flare vs. those
who did not, regardless of treatment.17 The following efficacy
assessments were completed in period A for ADAew vs. PBO:
the proportion of patients who experienced flare, duration of
flare (calculated from the day that flare was first observed at
scheduled visit to the day prior to the observation that flare was
no longer present), and time to flare. In period B, the proportion
of patients on continuous ADAew through 36 weeks who flared
was assessed.
As described earlier, patients who experienced either a loss of
response or a worsening or lack of improvement during period
B escaped early into the OLE to receive ADAew. As expected,
many of the patients on PBO in period B were rescued into the
OLE once they met the escape criteria and before experiencing a
protocol-defined flare. Therefore, there were not enough
patients on PBO remaining in period B who were experiencing
disease flare to make a robust comparison vs. ADAew through
36 weeks.
Statistical analysis
Efficacy variables were assessed in the following patient popula-
tions: (i) the intent-to-treat period A population, defined as all
patients who were randomized at baseline (week 0); and (ii) the
intent-to-treat period B ADAew/ew population, defined as
patients randomized to ADAew in period A and re-randomized
to ADAew in period B (including those who escaped period B
early due to loss of response or worsening or absence of
improvement and continued ADAew treatment in the OLE).
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The Cochran–Mantel–Haenszel test was used to analyse the
treatment difference in the proportion of patients who experi-
enced flare in period A, adjusting for study, baseline Hurley
stage and concomitant use of antibiotics at baseline; 95% confi-
dence interval (CI) was calculated using the extended Mantel–
Haenszel statistic. Analysis of covariance was used to analyse the
treatment difference in the number of days on flare in period A,
with strata (study, baseline Hurley stage and concomitant use of
baseline antibiotics) and treatment in the model. Kaplan–Meier
plot plus log-rank test and corresponding summary statistics
were used to analyse the treatment difference in time to flare in
period A. Fisher’s exact test was used to analyse the treatment
difference in adverse events of worsening HS in period A. Miss-
ing data were handled by non-responder imputation analysis for
categorical data and last-observation-carried-forward analysis
for continuous data. Descriptive analyses were conducted by
treatment sequence group.
Results
Patients
A total of 633 patients were included in period A (316 in
the ADAew group and 317 in the PBO group). A total of 99
patients were randomized to ADAew in period A and were
Period A
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12 weeks
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Double-blind placebo-controlled
24 weeks
Adalimumab 
160 mg (week 0), 
80 mg (week 2), 
followed by 40 mg 
weekly(ADAew)
Placebo
(PBO)
ADA 40 mg every other week (ADAew/eow)
Placebo (ADAew/PBO)
Placebo (PBO/PBO)§
ADA 40 mg weekly (PBO/ADAew)‡
Week: 120 36
PIONEER I and II
Open-Label Extension (OLE)¶
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At least 60 weeks
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period B: Option to 
enter OLE starting at 
week 16
OR OR
At completion of 
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Figure 1 PIONEER study schematic. *Stratiﬁed by baseline Hurley Stage II vs. III (PIONEER I & II) and baseline concomitant antibiotic
use (PIONEER II). Rerandomization at entry to period B, stratiﬁed by week 12 HiSCR status and BL Hurley Stage II vs. III. ‡PIONEER I only
(160 mg week 12, 80 mg week 14, 40 mg from week 16). §PIONEER II only. ¶OLE entry criteria: completed PIONEER I or II or met pre-
speciﬁed escape criteria (LOR or WOAI in period B). LOR was deﬁned as a count greater than the average AN count at baseline and at
week 12. Patients who achieved HiSCR at week 12 and experienced LOR during period B were discontinued from the study and were eli-
gible to enter the OLE and receive open-label ADAew. WOAI was deﬁned as AN count greater than or equal to baseline AN count at two
consecutive visits (excluding week 12) occurring ≥ 14 days apart. Patients who did not achieve HiSCR at week 12 continued in period B
through at least week 16 (and up to week 36). At or after week 16, patients who experienced WOAI were discontinued from the study and
were eligible to enter the OLE study to receive open-label ADAew. ADA, adalimumab; AN, sum of inﬂammatory nodules and abscesses;
BL, baseline; ew, every week; eow, every other week; HiSCR, hidradenitis suppurativa clinical response; LOR, loss of response; OLE,
open-label extension; PBO, placebo; WOAI, worsening or absence of improvement.
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re-randomized to ADAew in period B (Table 1). Patient demo-
graphics and baseline characteristics were generally similar
between groups. There were approximately two times as many
women as men, and the proportion of patients classified as hav-
ing Hurley stages II and III was similar within groups. The over-
all number of lesions at baseline was also similar between
groups.
Efﬁcacy assessments
Impact of ﬂare on quality of life Quality of life at week 12, as
assessed by DLQI, was significantly improved from baseline in
patients who did not experience flare compared with those who
did, with a least-squares mean (95% CI) difference of 3.9 (4.8
vs. 0.9 for no flares vs. flares; P < 0.001) (Fig. 2a). The propor-
tion of patients who achieved DLQI scores of 0–1 at week 12 was
significantly higher for patients who did not experience flare
compared with patients who did (P = 0.009; Fig. 2b).
Period A During period A, the proportion of patients experi-
encing at least one occurrence of flare was significantly lower in
the ADAew group compared with the PBO group at each visit
and overall (12.3% [n = 39] vs. 35.3% [n = 112]; P < 0.001;
Fig. 3). In addition, mean time to flare was significantly longer
for patients taking ADAew vs. those taking PBO (101 days vs.
Table 1 Patient demographics and baseline characteristics (ITT population)
Characteristic Period A Period B
ADAew (n = 316) PBO (n = 317) ADAew/ADAew (n = 99)
Age, years 35.5 (10.4) 37.0 (11.8) 34.8 (10.2)
Mean (SD)
Sex, n (%)
Female 199 (63.0) 218 (68.8) 66 (66.7)
Male 117 (37.0) 99 (31.2) 33 (33.3)
Race, n (%)
White 259 (82.0) 248 (78.2) 90 (90.9)
Black 42 (13.3) 49 (15.5) 6 (6.1)
Other 15 (4.7) 20 (6.3) 3 (3.0)
BMI, kg/m2 N = 315 N = 315 32.1 (6.9)
Mean (SD) 32.2 (7.6) 33.7 (8.0)
Hurley Stage, n (%)
II 166 (52.5) 170 (53.6) 49 (49.5)
III 150 (47.5) 147 (46.4) 50 (50.5)
Duration of HS, years 11.3 (8.8) 11.7 (9.1) 11.8 (8.8)
Mean (SD)
Lesion counts, mean (SD)
AN 12.4 (10.3) 13.1 (13.0) 12.1 (10.1)
Abscess 2.4 (3.1) 2.6 (3.5) 2.0 (2.6)
Inﬂammatory nodule 10.0 (9.2) 10.5 (11.9) 10.1 (9.4)
Draining ﬁstula 3.8 (4.7) 3.8 (4.8) 3.6 (4.2)
Modiﬁed Sartorius Score
Mean (SD) 128.6 (109.9) 134.6 (93.2) 137.3 (152.1)
Range 18–1093 20–531 20–1093
Current nicotine user, n (%) 186 (58.9) 201 (64.0) 59 (59.6)
ADAew, weekly adalimumab; AN, sum of inﬂammatory nodules and abscesses; BMI, body mass index; HS, hidradenitis suppurativa; hs-CRP, high-sensitivity
C-reactive protein; PBO, placebo; SD, standard deviation.
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Figure 2 DLQI during period A among patients who experienced
ﬂares compared with patients who did not experience a ﬂare. (a)
Least-square mean (SE) change from baseline in DLQI; (b) propor-
tion of patients who achieved DLQI score 0–1 at week 12. DLQI,
Dermatology Life Quality Index; SE, standard error. *P = 0.009;
**P < 0.001.
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57 days; P < 0.001; Fig. 4a), and duration of flare was signifi-
cantly lower in ADAew-treated patients compared with PBO-
treated patients (mean of 18.9 days vs. 32.0 days, respectively;
P = 0.001; Fig. 4b). The proportion of patients experiencing
multiple flares was also lower in the ADAew group vs. PBO
group (5.4% vs. 17.7%, respectively; P < 0.001).
Period B Among all patients who received continuous ADAew
treatment during periods A and B (n = 99), 20.2% experienced
flare between weeks 12 and 36. Among these patients, for those
who had at least a partial initial response to ADAew at week 12
(defined as ≥ 25% improvement in total AN count relative to
baseline; n = 70), only 5.7% experienced flare at any time
between week 12 and week 36 (Fig. 5).
Discussion
The impact of HS on quality of life is higher than other derma-
tological conditions.18,19 For general inflammatory skin
conditions, a change in DLQI score of ≥ 4 points is considered
clinically important.20 In this analysis at week 12, the average
improvement in DLQI from baseline was 4.8 points for patients
who did not experience flare compared with 0.9 points for those
who did, suggesting that prevention of flare is associated with a
clinically relevant impact on HRQOL. Additionally, the propor-
tion of patients who reported that HS had no effect at all on
their life (DLQI score of 0–1) was also significantly higher for
patients who did not experience flare (P < 0.001), further sup-
porting the finding that flare plays an important role in the qual-
ity of life of patients with HS.
The results of this analysis demonstrate that ADAew is
effective at preventing flares in the short and longer-term
treatment of patients with moderate-to-severe HS. During the
12-week PBO-controlled portion of the study, the proportion
of ADAew patients experiencing flare was only about one-
third that of the proportion of PBO patients experiencing
flare (12.3% vs. 35.3%), and few ADAew patients experienced
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multiple flares (5.4%). Furthermore, between weeks 12 and
36, most patients receiving continuous ADAew (80%) did
not experience disease flare. Importantly, flare prevention
over the longer-term was most marked in those with at least
a partial response to ADAew at week 12, as 94.3% of these
patients experienced no flares between weeks 12 and 36. In
addition to significantly reducing the proportion of patients
who flare, ADA demonstrated improvement in flare-related
parameters vs. PBO, including longer time to flare (over
100 days to first flare vs. 57 days in terms of the 25% quan-
tile; median time not estimable due to the fact that too few
patients experienced flare) and noticeably shorter flare dura-
tion (> 13 days shorter flare on average).
Previous reports from the PIONEER I and II studies also
demonstrate the efficacy of ADAew treatment in HS, with signif-
icantly higher clinical response rates vs. placebo at week 12.13,14
Long-term efficacy with continuous weekly ADA was assessed
through the 3-year OLE, demonstrating that the percentage of
patients achieving clinical response remained consistent through
168 weeks.
Reinforced by the flare data presented here, continuous
weekly ADA appears to be the optimal strategy for maintenance
of disease control, especially in those patients who achieve at
least a partial response by week 12. This finding was also sup-
ported across multiple efficacy parameters in the integrated anal-
ysis of the PIONEER I and II trials.21 It should be noted that,
given the waxing and waning nature of disease activity in HS,
patients can expect some degree of disease variation even with
ADAew. However, patients appear to experience considerably
less variation with continued weekly ADA treatment: in the anal-
ysis by Jemec et al. median worsening in AN count from week
12 at the worst point throughout period B was 1 (interquartile
range 0–4) for patients continuing ADAew, while patients who
withdrew from ADAew in period B had a median worsening of 3
(interquartile range 1–6).21 A multimodal approach can be con-
sidered to manage those patients who do experience occasional
flare with intralesional corticosteroids, analgesics, antibiotics,
deroofing, and incision and drainage.
Limitations of the current analysis include the lack of a
reliable control group past 12 weeks of the PIONEER pro-
gramme; as such, it is difficult to determine how flare inci-
dence on ADAew treatment compares with that of the
natural course of disease over the long term. Additionally,
the definition of flare used in this analysis was developed as
an objective and measurable outcome for reporting purposes.
We also acknowledge that the study population was limited
to patients with moderate-to-severe HS, and therefore may
not represent all patients with HS.
Additional research is needed to examine factors associated
with HS flare and the impact of longer-term ADAew treatment
on flare. A well-established and validated definition of flare is
also needed for clinical research purposes, along with additional
treatment targets in HS.
Conclusions
This analysis provides valuable insight into the impact of disease
flare on patients with HS, as there is a clinically insignificant
change in quality of life in patients who experience flare; and a
5 9 higher improvement in DLQI in patients who did not flare.
As such, incidence of flare and associated measures should con-
tinue to be evaluated in future clinical trials for HS. These data
demonstrate the positive effect of weekly adalimumab treatment
on incidence of HS disease flare, time to flare and duration of
flare. Importantly, this analysis also further supports the use of
continued weekly adalimumab treatment in patients experienc-
ing at least a partial response at week 12, which resulted in com-
plete flare prevention in about 95% of patients through
36 weeks of treatment.
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